source
- Ensoma cuts staff again to focus on lead gene therapy for rare immune diseaseBoston‑based biotech Ensoma announced another round of layoffs as it narrows its efforts to its sole clinical candidate, EN‑374, aimed at treating X‑linked chronic granulomatous disease (X‑CGD). E…
- FDA outlines inspection overhaul, proposes IND reforms, and greenlights a disputed cancer therapyFDA officials announced a plan to restructure the agency’s inspectional operations, aiming to make inspections more efficient and focused. The proposed changes include consolidating regional office…